Neutra Corp. announced the appointment of Richard C Kaufman to spearhead its new research and development projects in the nutraceuticals industry, including projects targeting the medical cannabis sector. In his new role, Dr. Kaufman, who has over 30 years of experience as an executive nutraceuticals product developer and researcher, will lead the company's efforts to develop and market the next generation of custom nutraceutical delivery systems, particularly those engineered to improve products and services in the US MMJ market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0003 USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 875K | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- NTRR Stock
- News Neutra Corp.
- Neutra Corp. Names Richard C Kaufman as Head of New Research and Development